MarketPeel
Insider Trading Intelligence
Pricing
…
AP

Arian Pano

KNSA
CHIEF CLINICAL DEV. OFFICER · KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC · CIK 0001867891
FILING MIX · LIFETIME100%/0%
BUYS
2
SELLS
0
TOTAL VALUE
$0
COMPANIES
1
ACTIVE SINCE
Sep 2021
HOLDINGS NOW
3,888
AVG SELL PX
—
TRADE KIND
SHOWING 2 / 2
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
No backtest data available for Arian Pano. Backtests are computed for purchase (P) and sale (S) transactions with resolvable price history.
Holdings over time
KNSA · 3,888 shares · as of Sep 2, 2021
05,83111,66317,49423,325SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
FLOW · 2 buys / 0 sellsCOVERAGE · 1 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
PURCHASEGRANT
Stock grant
23,325——23,325Sep 2, 2021Sep 7, 2021 ↗View →
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
PURCHASEGRANT
Stock grant
3,888——3,888Sep 2, 2021Sep 7, 2021 ↗View →
Other insiders · KNSA
Loading peer insiders…
About this filer
CIK 0001867891
ROLE
Chief Clinical Dev. Officer
PRIMARY
KNSA
COMPANIES
1
ACTIVE SINCE
Sep 2021
MARKETPEEL · /INSIDER/0001867891DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback